| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors | N/A | University of Colorado, Denver | <1 mi |
| A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | Phase 3 | Colorado Prevention Center | <1 mi |
| Bright Light Exposure in Surgical Patients | N/A | University of Colorado, Denver | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | <1 mi |
| MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation | N/A | University of California, San Francisco | <1 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | <1 mi |
| Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver | N/A | Denver Health and Hospital Authority | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | 5 mi |
| Product Surveillance Registry | — | Medtronic | 5 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | 6 mi |
| Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | Phase 2/3 | Kiniksa Pharmaceuticals International, plc | 7 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | 8 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | 8 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | 8 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | 8 mi |
| A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists | Phase 3 | Colorado Prevention Center | 8 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | 8 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | 8 mi |
| Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Phase 3 | NYU Langone Health | 8 mi |
| Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC | Phase 1 | Tenaya Therapeutics | 8 mi |
| The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. | — | Heart Rhythm Clinical and Research Solutions, LLC | 8 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | 8 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | 8 mi |
| CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation | N/A | University of Colorado, Denver | 8 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | 8 mi |
| A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | 8 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | 8 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | 8 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | 8 mi |
| Simulation Trial of Telemedical Support for Paramedics | N/A | Boston Medical Center | 8 mi |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | 8 mi |
| Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease | N/A | University of Colorado, Denver | 8 mi |
| Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | — | Tenaya Therapeutics | 8 mi |
| Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass | N/A | University of Colorado, Denver | 8 mi |
| Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders | Phase 3 | Ascendis Pharma A/S | 8 mi |
| Optimizing Pulsatility During Cardiopulmonary Bypass | — | University of Colorado, Denver | 8 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | 8 mi |
| Digital Health Physical Activity Program for Older Family Care Partners of Patents With Heart Failure | N/A | University of Colorado, Denver | 8 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | 8 mi |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | 8 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 8 mi |
| Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease | N/A | Colorado Prevention Center | 8 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | 8 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | 8 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | 8 mi |
| Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day | — | Heart Rhythm Clinical and Research Solutions, LLC | 8 mi |
| Minima Stent System Post- Approval Study (PAS) | — | Renata Medical | 8 mi |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | — | Mirum Pharmaceuticals, Inc. | 8 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | 8 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | 8 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | 8 mi |
| Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs | — | Inova Health Care Services | 8 mi |
| Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure | N/A | University of Colorado, Denver | 8 mi |
| Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry | — | University of Colorado, Denver | 8 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | 8 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 8 mi |
| Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study | N/A | Starlight Cardiovascular Inc | 8 mi |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | Novartis Pharmaceuticals | 8 mi |
| A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study | N/A | Carelon Research | 8 mi |
| Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome | Phase 3 | University of Colorado, Denver | 8 mi |
| A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation | N/A | Biosense Webster, Inc. | 8 mi |
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | 8 mi |
| Using CTA Measures to Define Cardiac Risk In NFL Alumni | — | HeartFlow, Inc. | 9 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | 9 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | 9 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | 9 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | 9 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | 9 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | 9 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | N/A | Cardiac Dimensions, Inc. | 9 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | 9 mi |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | 9 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | 9 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | 9 mi |
| Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization | — | HemoCept Inc. | 24 mi |
| Detecting Changes in Arterial Blood Volume and Cardiac Efficiency | — | HemoCept Inc. | 24 mi |
| Randomization of Single vs Multiple Arterial Grafts | N/A | Weill Medical College of Cornell University | 24 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | 46 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | 46 mi |
| Prevail Global Study | N/A | Medtronic Vascular | 46 mi |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | 46 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | 46 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 46 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | 46 mi |
| ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | N/A | Edwards Lifesciences | 46 mi |